| Document Date: 2012-11-06 14:16:29
Open Document File Size: 75,23 KBShare Result on Facebook
City Williston / / Company Novartis / Merck / Sanofi / Teva / HP / Novo Nordisk / / Event FDA Phase / Natural Disaster / / Facility p.m.* HP Building / / IndustryTerm preferred branded product / Diabetes Care / / MedicalCondition seizures / pulmonary arterial hypertension / multiple sclerosis / II diabetes mellitus AND / actinic keratosis AND / MS / ADHD / pulmonary hypertension / allergy / recently evaluated seizure / pain / heart failure / respiratory depression / obstructive sleep apnea syndrome / / Organization DUR Board / FDA / Next DUR Board / Access Pharmacy Benefit Management Program DUR Board / / Person Justin Bakhshai / Mark Pasanen / Mary Beth Bizzari / Kim Ladue / Michelle Sirois / Respiratory Jaskanwar Batra / Diane Neal / Amanda Kennedy / Gary Starecheski / Halle Sobel / Session / Stacey Baker / Joseph Lasek / Matt Badalucco / Kurt Buckner / Jennifer Egelhof / Jessica Kritzman / Catamaran Mary / Gary Karg / Michael Farber / Terry Eagan / Melissa Guiles / Jeanne Greenblatt / / Position Director Update / Pharmacy Director / Medical Director / Executive / Chair / Miner / / Product Synagis / Janumet / Eurax / Tranxene / Byetta / Cymbalta / Oral Tablet / Klonopin / Valium / Focalin XR / Revatio / diazepam / Travatan Z / Strattera / chlorthalidone / Lyrica / Aldara / Lumigan / fluorouracil / Oxecta® (oxycodone) Tablet / Victoza® DVHA DUR Board / Strattera® / Zioptan® / Victoza / Byetta® Or / Edarbyclor® / Byetta® / Bydureon® / Bydureon / Janumet XR® / Picato® / Klonopin® / / ProvinceOrState Vermont / /
SocialTag |
Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: [removed]Board Members: Present: Joseph Lasek, MD, Chair